Previous 10 | Next 10 |
2023-03-07 10:35:21 ET Alaunos Therapeutics, Inc. (TCRT) Q4 2022 Earnings Conference Call March 7, 2023 08:30 AM ET Company Participants Danielle Dudgeon - Stern IR Kevin Boyle Senior - CEO Drew Deniger - VP, Research and Development Abhi Srivastava - VP, Tec...
2023-03-07 07:03:53 ET Alaunos Therapeutics press release ( NASDAQ: TCRT ): Q4 GAAP EPS of -$0.04 beats by $0.03 . As of December 31, 2022, Alaunos had approximately $53.0 million in cash balances, which includes restricted cash of approximately $13.9 million. Base...
Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T efforts Advancing TCR-T Library Program towards Phase 2 readiness with accelerated patient enr...
2023-03-06 11:10:18 ET Alaunos Therapeutics ( NASDAQ: TCRT ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, before markets open. The consensus EPS Estimate is -$0.07 (-40.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 1 year, TCRT ...
2023-03-06 10:17:11 ET Major earning expected before the bell on Tuesday include: Canaan ( CAN ) DICK'S Sporting Goods ( DKS ) Sea ( SE ) Alaunos Therapeutics ( TCRT ) Thor Industries ( THO ) For further details see: Notable earnings befor...
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended D...
Summary A third patient dosed last quarter should have 12-week data next month. However, the company promised a mid-year readout. Its cell therapy library is expanding, although really not doubling its potential market. Last month, Alaunos Therapeutics ( TCRT ) highlighted...
Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform Increasing patient enrollment to advance TCR-T Library Program towards Phase 2 using high value TCRs targeting c...
Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? PR Newswire NEW YORK , July 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ...
We’re in the final stretch of June 2022 and the last few days of the second quarter. Gross Domestic Product results for the quarter and additional CPI data are also due out before July. Whether they reveal a recession, higher inflation, or something completely different may not matte...
News, Short Squeeze, Breakout and More Instantly...
Alaunos Therapeutics Inc. Company Name:
TCRT Stock Symbol:
NASDAQ Market:
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...